FDA Defends Abortion Pill Decisions From Blue State Challenge

The Food and Drug Administration is defending safety decisions it made on the abortion drug mifepristone against a legal challenge from over a dozen states and the District of Columbia.

In an attempt to broaden access to abortion while the procedure was being limited across the country, liberal-leaning states led by Washington state sued the FDA to eliminate prescriber certification requirements and a patient agreement form on the drug.

In a Wednesday motion for summary judgment, the FDA is defending its decisions, calling them necessary for mitigating risks involving missed ectopic pregnancy, heavy bleeding, and more. The case is ...